Previous Close | 233.16 |
1-Year Change | 37.68% |
6-Months Change | -9.97% |
3-Months Change | -12.93% |
Moving Avg (50d) | 258.22 |
Moving Avg (200d) | 242.61 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 4.31B |
Beta (3-Years) | 0.81 |
Revenue Growth (ttm) | % |
Net Profit Margin (ttm) | % |
Return On Assets (ttm) | -145.96% |
EPS (ttm) | -19.24 |
PE Ratio (ttm) | -12.12 |
Dividend Yield | % |
Asset Description: | Madrigal Pharmaceuticals, Inc. |
Predicted Direction: | Buy |
Signal Strength: | Neutral |
Forecast Date: | 2024-09-13 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
228.497 | 221.502 | 216.839 | 209.844 | 198.186 | 186.528 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.